These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Search MEDLINE/PubMed

  • Title: The influence of nutritional status, dialysis adequacy, and residual renal function on the response to hepatitis B vaccination in peritoneal dialysis patients.
    Author: Dacko C, Holley JL.
    Journal: Adv Perit Dial; 1996; 12():315-7. PubMed ID: 8865927.
    Abstract:
    Little is known about the factors contributing to the reduced antibody response to hepatitis B vaccination in peritoneal dialysis patients. The influence of nutritional status [as assessed by serum albumin and nitrogen protein appearance (nPNA)], residual renal function, and dialysis adequacy (weekly Kt/V(urea)) on the development of hepatitis B antibodies was examined in 32 continuous ambulatory peritoneal dialysis/continuous cycling peritoneal dialysis patients. Vaccination with Engerix 40 micrograms given intramuscularly at 0, 1, 2, and 6 months resulted in a 63% response with 20 converters and 12 nonconverters. Patient age, sex, months on peritoneal dialysis, and race were not different among converters and nonconverters. Median serum albumin (3.75 vs 3.8 g/dL), nPNA (0.96 vs 0.94 g/kg/day initial and 0.78 vs 0.84 g/kg/day final), residual renal function (5.4 vs 4.0 mL/min), and final weekly Kt/V (2.12 vs 1.96) were not different among converters and nonconverters, respectively. Initial Kt/V was higher in converters (2.37 vs 2.01, p = 0.02). Nutritional status, residual renal function, and weekly Kt/V in nutritionally replete and well-dialyzed peritoneal dialysis patients do not predict response to hepatitis B vaccine. Patients with higher weekly Kt/V early in the course of peritoneal dialysis may be more likely to respond to hepatitis B vaccination.
    [Abstract] [Full Text] [Related] [New Search]